Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies
A $2.88 billion deal is set to reshape the autoimmune drug landscape.
Evidence dossier
Intelligence passport
Measured timeline
- Detected The first matching coverage entered the Archynetys cluster.
- Evidence threshold reached The story had enough independent coverage for an explanatory brief.
- Latest coverage observed Most recent article currently attached to this story cluster.
- Peak measured velocity The recorded velocity reached 5.
Source diversity sample: PR Newswire · BioPharma Dive · usaherald.com · PharmExec.com · Law360 · BioSpace · Fierce Biotech.
How this dossier is built: methodology · AI policy · corrections.
Sources (7)
- Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases PR Newswire · 15h ago
- Lilly adds to immune drug pipeline with $2.9B Merida buyout BioPharma Dive · 15h ago
- Eli Lilly to Buy Merida in Bet on Eliminating Disease at Its Source usaherald.com · 15h ago
- Eli Lilly Enters $2.8 Billion Agreement to Acquire Merida Biosciences PharmExec.com · 15h ago
- Ropes-Steered Lilly To Buy Goodwin-Led Merida For $2.9B Law360 · 15h ago
- Deal-hungry Lilly strikes up to $2.9B immuno play for Merida BioSpace · 15h ago
- Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies Fierce Biotech · 15h ago
Where it stands
The pharmaceutical industry is abuzz with Eli Lilly's acquisition of Merida Biosciences. The buyout is poised to revolutionize treatment for autoimmune diseases by targeting rogue antibodies.
The deal, valued at $2.88 billion, underscores Eli Lilly's strategic move to eliminate diseases at their source. The acquisition is steered by Ropes & Gray for Lilly and Goodwin Procter for Merida, according to Law360.
The buyout is framed as a bet on innovative immuno therapies. The open question is how this acquisition will impact the competitive landscape and the development of new treatments.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 7h ago.
Answered
What is the value of the Eli Lilly Merida acquisition?
$2.88 billion.
What is the strategic focus of the acquisition?
The acquisition targets autoimmune diseases by focusing on rogue antibodies.
Which law firms are involved in the acquisition?
Ropes & Gray is representing Eli Lilly, and Goodwin Procter is representing Merida.
How fast it spread
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Topics
Related trends
Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers
Nearly a dozen drugmakers are poised to announce new pricing deals with the Trump administration.
Eli Lilly to Buy Merida Biosciences for Up to $2.875 Billion
Eli Lilly's acquisition of Merida Biosciences for up to $2.875 billion is making waves in the biotech industry.
US FDA approves Lilly's Mounjaro to reduce cardiovascular risk
The FDA's approval of Lilly's Mounjaro for cardiovascular risk reduction is a major win for the company and a potential game-changer for diabetes patients.
China is a Threat to Biotech’s Massive Bull Run
Congress pushes a China‑targeted biotech shield even as the sector rides a historic bull run.
The Medicare GLP-1 Discount Has One Big Catch: Some Sick Patients Don’t Qualify
Millions of Medicare patients with qualifying diagnoses are excluded from a new GLP-1 discount program.
Founded by Metsera backers, Sentivera emerges with $1.5B inflammatory disease deal
A $1.5 billion China‑U.S. biotech pact puts American VCs and Haisco at the center of a new inflammatory‑disease platform.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.